Condition: Angiosarcoma of Skin · Angiosarcoma Metastatic · Sponsor: National Cancer Center, Japan
Cutaneous angiosarcoma is a rare cancer for which effective treatment has not been developed sufficiently. Still, because it often occurs in elderly people, the number of patients is increasing due to the aging population. Cutaneous angiosarcoma is difficult to completely remove by surgery, and recurrence and metastasis after surgery are not uncommon. Therefore, chemotherapy, radiation therapy, and a combination of these are currently widely used as treatments. Traditionally, the anticancer drug used for cutaneous angiosarcoma was mainly doxorubicin. In recent years, it has been reported that cancer shrank in 18% of patients after two months of paclitaxel administration in a clinical trial. Therefore, paclitaxel has become more commonly used for cutaneous angiosarcoma. Other options include anthracycline anticancer drugs and gemcitabine. However, even with these anticancer drugs (and radiation therapy), cutaneous angiosarcoma progresses quickly, and some reports have said that the 5-year survival rate is 9%. This study is planned to develop a safer and more effective treatment for cutaneous angiosarcoma and will include 38 participants. In this study, eligible participants will receive combination chemotherapy with 200 mg of pembrolizumab (injection liquid, once every 3 weeks) and 20 mg of lenvatinib (capsule, once daily) for up to approximately two years as protocol treatment unless the criteria for termination meet. Before, during, and after the protocol treatment, particip…
This description comes directly from the study's public registry record.
Dai Ogata, M.D., Ph.D. · +81.3.3542.2511 · dogata@ncc.go.jp
Eiji Nakano, M.D., Ph.D. · +81.3.3542.2511 · einakano@ncc.go.jp
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital East | Kashiwa, Japan | Recruiting |
| University Hospital Kyoto Prefectural University of Medicine | Kyoto, Japan | Recruiting |
| Faculty of Medicine, University of Miyazaki Hospital | Miyazaki, Japan | Recruiting |
| Nagoya City University Hospital | Nagoya, Japan | Recruiting |
| Keio University Hospital | Tokyo, Japan | Recruiting |
| National Cancer Center Hospital | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06673628